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Objective. Inhibition of T cell DNA methylation
causes autoreactivity in vitro and a lupus-like disease in
vivo, suggesting that T cell DNA hypomethylation may
contribute to autoimmunity. The hypomethylation ef-
fects are due, in part, to overexpression of lymphocyte
function–associated antigen 1 (LFA-1) (CD11a/CD18).
Importantly, T cells from patients with active lupus
have hypomethylated DNA and overexpress LFA-1 on
an autoreactive subset, suggesting that the same mech-
anism could contribute to human lupus. The present
study investigated the nature of the methylation change
that affects LFA-1 expression in vitro and in human
lupus.
Methods. Bisulfite sequencing was used to deter-
mine the methylation status of the ITGAL promoter and
flanking regions in T cells from lupus patients and
healthy subjects, and in T cells treated with DNA
methylation inhibitors. “Patch” methylation of pro-
moter sequences in reporter constructs was used to
determine the functional significance of the methylation
changes.
Results. Hypomethylation of specific sequences
flanking the ITGAL promoter was seen in T cells from
patients with active lupus and in T cells treated with
5-azacytidine and procainamide. Patch methylation of
this region suppressed ITGAL promoter function.
Conclusion. DNA methylation changes occur in
specific sequences that regulate LFA-1 expression in
lupus T cells and in the hypomethylation model, indi-
cating that altered methylation of specific genes may
play a role in the pathogenesis of lupus.
The mechanisms initiating human systemic lupus
erythematosus (SLE) remain unknown. The finding that
exposure to certain drugs can induce a lupus-like disease
has provided leads into the nature of biochemical alter-
ations associated with lupus. The 2 drugs most fre-
quently associated with lupus, procainamide and hydral-
azine, can cause a lupus-like disease through effects on
T cell DNA methylation. Treating T cells with procain-
amide, hydralazine, or 5-azacytidine (5-azaC; the proto-
typic DNA methylation inhibitor) demethylates DNA,
alters gene expression, and induces major histocompat-
ibility complex–specific T cell autoreactivity (1–5).
Adoptive transfer of the autoreactive cells causes a
lupus-like disease in animal models (5–7). The auto-
immune effects of the methylation inhibitors are due,
in part, to overexpression of lymphocyte function–
associated antigen 1 (LFA-1) (CD11a/CD18), because
increasing T cell LFA-1 by transfection causes an iden-
tical autoreactivity in vitro, and a similar autoimmune
disease in vivo (4,8).
Altered DNA methylation has also been impli-
cated in human lupus. T cells from patients with active
lupus have an 17% decrease in genomic deoxymethyl-
cytosine content and overexpress LFA-1 on an autore-
active subset (9–11). However, whether the DNA hy-
pomethylation occurring in lupus affects transcriptionally
relevant regions is not known. It is similarly unknown if
the DNA hypomethylation induced by 5-azaC or pro-
cainamide affects the same sequences as those affected
in SLE.
DNA methylation inhibitors increase LFA-1
through their effects on the gene encoding CD11a (9),
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termed ITGAL (derived from Integrin Alpha L). The
promoter of this gene contains PU.1 and Sp1 binding
elements within 120 bp of the transcription start site, and
the 40-bp fragment located 5 to the transcription start
site is necessary for most of the promoter activity in T
cells (12).
To determine if altered ITGAL methylation
could cause autoimmunity in the DNA hypomethylation
model of lupus and in idiopathic lupus, and to extend the
previous association of genome-wide demethylation and
autoimmunity to specific, transcriptionally relevant se-
quences, we determined the methylation status of se-
quences in or near the ITGAL promoter in 5-azaC–
treated and procainamide-treated cells and in lupus T
cells. We also determined the effect of altered methyl-
ation of specific sequences on CD11a expression.
PATIENTS AND METHODS
Human subjects. Patients with SLE and patients with
rheumatoid arthritis (RA) were recruited from the outpatient
clinics and inpatient rheumatology service at the University of
Michigan. Patients with SLE or RA met the criteria for their
respective diseases (13,14), and SLE disease activity was
assessed using the SLE Disease Activity Index (SLEDAI) (15).
Inactive disease was defined as a SLEDAI score 4, and active
disease as a SLEDAI score 5. The clinical characteristics of
the patients and controls are listed in Table 1.
T cell isolation and culture. Peripheral blood mono-
nuclear cells (PBMCs) were isolated by density gradient
centrifugation and T cells were purified by e-rosetting as
described previously (9), and the CD4 subset was isolated by
magnetic cell sorting using CD4 microbeads (Miltenyi Biotec,
Auburn, CA). Where indicated, the cells were stimulated with
phytohemagglutinin (PHA) (9), treated with 1 M 5-azaC
(Fluka, Milwaukee, WI), 50 M procainamide (Sigma, St.
Louis, MO), or 10 M dexamethasone (Aldritch, Milwaukee,
WI), and cultured for 3 days as previously described (1). Jurkat
T cells were cultured as previously described (1). Proliferation
assays were performed as described (3), using 2  104 T cells
and irradiated autologous PBMCs as antigen-presenting cells.
Flow cytometric analysis. T lymphocytes were analyzed
for CD2 and CD11a expression using 2-color flow cytometry
and fluorescein isothiocyanate– or phycoerythrin-conjugated
monoclonal antibodies from PharMingen, as previously de-
scribed (9). Each lupus patient was analyzed in parallel with at
least 1 healthy control. The CD11a mean channel fluorescence
(MCF) was calculated for each patient and subject, and results
were tabulated as the patient:subject MCF ratio.
Bisulfite sequencing. One to five micrograms of puri-
fied T cell DNA was treated with sodium bisulfite (16), and
then the 2.3-kb CD11a promoter fragment (12) was amplified
in 5 overlapping fragments. The fragments were cloned into
PBS (Stratagene, La Jolla, CA), and 5 independent clones
were sequenced by the University of Michigan Sequencing Core
for each of the amplified fragments.
Patch methylation. A 1.9-kb fragment containing the
human ITGAL promoter (accession number M87662; kindly
provided by Dr. Dennis Hickstein, NIH, Bethesda, MD) was
cloned into the luciferase-containing reporter vector pGL3-
Basic (Promega, Madison, WI). An Nde 1 site was engineered
into the promoter at bp 382 using the QuikChange site-
directed mutagenesis kit (Stratagene), and intact function was
confirmed by transfection into Jurkat cells. The region from
the beginning of the fragment to the Nde 1 site was excised,
methylated with Sss 1 and S-adenosylmethionine (both
from New England Biolabs, Beverly, MA) using instructions
provided by the manufacturer, and then ligated back into
the reporter construct and purified by gel electrophoresis.
Sss 1 catalyzes the transfer of methyl groups from S-
adenosylmethionine to unmethylated dC residues only in CpG
pairs (17). Completeness of methylation was tested by diges-
tion with the methylation-sensitive restriction endonuclease
(Aci 1) (New England Biolabs). Controls included a mock
methylated construct, prepared by omitting the Sss 1.
Transient transfection. Plasmid DNA was introduced
into Jurkat cells by electroporation using a modification of
previously described protocols (4,8). Twenty-four hours later,
the cells were washed twice, suspended in 400 l reporter lysis
buffer (Promega), and lysed by freeze–thaw. Insoluble material
was removed by centrifugation and luciferase assays were
performed using 100 l as described previously (18). Similarly,
20 l was used for -galactosidase determinations, which were
performed using the Galacto-Light system as per the manu-
facturer’s protocol (Tropix, Bedford, MA).
Quantitative reverse transcriptase–polymerase chain
reaction (RT-PCR) of CD11a messenger RNA (mRNA). Real-
time quantitative RT-PCR was performed using a LightCycler
(Roche, Indianapolis, IN) and previously published protocols
(19). A series of 5 dilutions of 1 RNA sample was also included
to generate a standard curve, and this was used to obtain
relative concentrations of the transcript of interest in each of
the RNA samples. Relative concentrations were then deter-
mined by the second derivative method using the LightCycler
computer software. Amplification of -actin was performed to
confirm that equal amounts of total RNA were added for each
sample and that the RNA was intact and equally amplifiable
Table 1. Clinical characteristics of the lupus patients*
Patient/age/
sex SLEDAI Medication
1/47/F 2 AZA, HCQ, low pred
2/37/M 2 HCQ
3/46/F 4 HCQ
4/40/F 4 HCQ, low pred
5/36/F 5 HCQ, moderate pred
6/53/F 7 HCQ
7/46/F 9 HCQ, high pred
8/48/F 10 AZA, HCQ,
moderate pred
9/30/F 12 CTX, HCQ, low pred
10/21/F 24 HCQ, high pred
* SLEDAI  Systemic Lupus Erythematosus Disease Activity Index;
AZA  azathioprine; HCQ  hydroxychloroquine; low pred  0.5
mg/kg/day prednisone; moderate pred  0.5–1.0 mg/kg/day pred-
nisone; high pred  1.0 mg/kg/day prednisone; CTX  cyclophos-
phamide.
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among all samples. The CD11a primers were as follows:
forward 5-AAATGGAAGGACCCTGATGCTC-3, back-
ward 5-TGTAGCGGATGATGTCTTTGGC-3. The -actin
primers were as follows: forward 5-GCACCACACC-
TTCTACAATGAGC-3, backward 5-GGATAGCACAG-
CCTGGATAGCAAC-3.
Statistical analysis. Data were analyzed using Stu-
dent’s t-test, regression analysis, or analysis of variance
(ANOVA) as appropriate, calculated with SyStat software
(Evanston, IL).
RESULTS
LFA-1 expression and disease activity. Previous
studies demonstrated that T cells from patients with
active lupus typically overexpress CD11a, with an overall
average increase of 40% (10). Figure 1A shows a
representative histogram of CD11a staining on peri-
pheral blood T lymphocytes from a patient with a
SLEDAI of 12 and from a normal healthy control.
Figure 1B shows the ratio of the CD11a MCF of T cells
from 6 of the lupus patients, who exhibited a range of
disease activity (Table 1), and from 6 paired, healthy
controls, plotted against the SLEDAI score. T cell
CD11a expression increased a mean 	 SEM of 60 	
17% (range 41–105%) with increasing disease activity in
the 4 subjects with active disease (P  0.026 by regres-
sion analysis).
ITGAL promoter methylation. We next deter-
mined the methylation pattern of the ITGAL promoter
and flanking sequences in 4–6 healthy controls. Figure
2A shows the 22 potentially methylatable CpG pairs
located 5 to the transcription start site, and the 5 pairs
following the start site. For reference, the transcription-
ally important PU.1 and Sp1 sites and the transcription
start site are also shown (12,20). Figure 2B shows the
methylation pattern of this region in T cells from healthy
controls. For each CpG pair, the methylation status was
assessed in 5 cloned fragments from each individual, and
the results are presented as the average (mean) methyl-
ation of the dC residue from the donors. The transcribed
region (3 to bp 0) was completely demethylated in all
fragments from the 4 healthy subjects examined, while
the majority of the sequences 5 to the start site were
Figure 1. Overexpression of lymphocyte function–associated antigen
1 (LFA-1) by lupus T cells. Peripheral blood mononuclear cells were
stained with anti–CD11a–fluorescein isothiocyanate and anti–CD2–
phycoerythrin and then analyzed by flow cytometry. A, Histogram of
LFA-1 expression on the CD2 cells from a patient with systemic
lupus erythematosus (SLE) and a healthy control. B, The CD11a mean
channel fluorescence (MCF) was determined for each 6 lupus patients
(pt) and 6 paired controls, and the ratio of patient to control MCF is
plotted against the SLE Disease Activity Index (SLE-DAI).
Figure 2. ITGAL promoter methylation in healthy controls. A, The 27
potentially methylated CpG pairs in the ITGAL promoter fragment
are identified by the “lollipops.” The transcriptionally relevant PU.1
and Sp1 sites and the transcription start site are also shown. B, T cell
DNA was isolated from heathy donors and treated with sodium
bisulfite, and then the fragment (shown in A) was amplified in
overlapping fragments. Five cloned fragments from each section were
then sequenced from each donor, and the fraction methylated for each
CpG pair was averaged across the 5 cloned and sequenced fragments.
The region from the beginning (1950 bp) to bp 1262 represents the
mean of 5 fragments from each of 4 donors, the region from 1261 to
68 (identified by the solid squares) shows the mean of 5 fragments
from each of 6 donors, and the region from 68 to the end shows the
mean of 5 fragments from each of 4 donors. The region containing Alu
elements is denoted by the horizontal line.
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partially methylated in all 6 controls. Of note is a region
containing Alu elements, which was more heavily meth-
ylated in all controls, consistent with previous reports
demonstrating that repetitive DNA sequences are usu-
ally heavily methylated (21).
ITGAL promoter methylation in lupus. Figure 3
compares the methylation pattern of the region from the
beginning of the Alu elements to the transcription start
site (bp 1261 to 68) in 3 lupus patients with varying
levels of disease activity. Ten of the 16 CpG pairs in this
region were relatively heavily methylated in a patient
with inactive lupus (SLEDAI of 2) (Figure 3A). In
contrast, the patient with very active lupus (SLEDAI of
24) (Figure 3C) had partial methylation of only 3 CpG
pairs in this region, while the patient with less active
lupus (SLEDAI of 12) showed an intermediate pattern
(Figure 3B). The 5 CpG pairs distal to the transcription
start site were also examined in 1 lupus patient and were
found to be unmethylated, similar to the findings in
controls. Methylation of this region would not be ex-
pected to affect transcription (22), and therefore this
region was not studied further.
Figure 3 also compares the average methylation
pattern across this region in T cells from 6 healthy controls
Figure 3. ITGAL promoter methylation in patients with systemic lupus erythematosus (SLE). The region from 1261 to 68 (identified by the
solid squares) was amplified and 5 fragments sequenced from a patient with A, inactive lupus (SLE Disease Activity Index [SLE-DAI] of 2), B,
active lupus (SLE-DAI of 12), and C, very active lupus (SLE-DAI of 24). Results are presented as averages, as shown in Figure 2. D, For
comparison, the average methylation at each CpG pair across the promoter fragment from 4–6 healthy donors is shown (as in Figure 2) versus
E, the average methylation of the CpG pairs in the 1261 to 68 fragment from 4 patients with inactive lupus (SLE-DAI of 4) and F, the
average methylation of the same region shown in E, using T cell DNA from 6 patients with active lupus (SLE-DAI of 5).
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(Figure 3D), 4 patients with inactive lupus (SLEDAI of
4) (Figure 3E), and 6 patients with active lupus (SLEDAI
of 5) (Figure 3F). The pattern in the patients with
inactive lupus resembled that in the healthy controls,
although the region between the Alu elements and the
transcription start site (bp 794 to 68) appeared some-
what more heavily methylated. In contrast, the patients
with active lupus had less methylation overall.
Figure 4A compares the average methylation of
the promoter between these 3 groups. For each subject,
the methylation status of all 16 CpG pairs in the region
from bp 1261 to 68 was averaged over the 4–5
sequenced fragments, and this number was then aver-
aged among the subjects in each group. This region was
significantly hypomethylated in the lupus T cells, relative
to that in both the controls and the patients with inactive
lupus (P  0.010 between groups, by ANOVA; P 
0.026 for active versus inactive lupus; P  0.007 for
active lupus versus controls, all by post hoc analysis).
Figure 4B plots the average methylation for each lupus
patient against the SLEDAI. Patients with more active
disease were more hypomethylated than were those with
inactive disease (P  0.010, by regression analysis).
Interestingly, the region between 794 and 68 (3 to
Figure 4. Relationship of ITGAL methylation to disease activity. A,
The methylation status of the CpG pairs in the 1261 to 68 fragment
was averaged among the 6 healthy control subjects, 4 subjects with
inactive systemic lupus erythematosus (SLE-i), and 6 subjects with
active SLE (SLE-a). Bars show the mean and SEM. P  0.026 versus
active SLE; P  0.007 versus controls. B, For each of the 10 lupus
patients (dotted squares), the fraction methylated from 1261 to 68
is plotted against the SLE Disease Activity Index (SLE-DAI).
Figure 5. ITGAL methylation in T cell subsets. DNA was isolated from A, CD4 T cells and B, CD8 T cells from a healthy
donor, C, CD4 T cells from a patient with active systemic lupus erythematosus (SLE) (SLE Disease Activity Index of 6), and
D, CD8 T cells from the same lupus patient. The region from 1261 to 68 (identified by the solid squares) is shown, and
represents the average methylation of 5 cloned and sequenced fragments.
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the Alu elements) was significantly more heavily meth-
ylated in the patients with inactive lupus relative to that
in the controls and that in the patients with active lupus
(P  0.010 and P  0.004, respectively, by ANOVA with
post hoc testing), suggesting the possibility of compen-
satory mechanisms (19,23).
The changes in methylation status in the lupus
patients were unlikely to be due to the types of medica-
tions being taken or the patient’s age (Table 1). Patient
6 was significantly hypomethylated but was only receiv-
ing hydroxychloroquine, similar to patients 2 and 3, who
also had greater methylation, arguing against an effect of
hydroxychloroquine. Similarly, patient 7 was receiving
high doses of corticosteroids but was more methylated
than patient 6. An effect of corticosteroids was further
excluded by treating normal T cells for 24 hours with 10
M dexamethasone. This did not significantly affect the
methylation status of the 13 CpG pairs between bp
1261 and 574 of the ITGAL promoter (mean 	 SEM
fraction methylated 0.42 	 0.12 versus 0.39 	 0.13 for
untreated versus treated groups, 10 fragments/group).
Similarly, there was no correlation of hypomethylation
with the use of immunosuppressives, since patients 6 and
10 had hypomethylated DNA but were not receiving
antimetabolites. Finally, regression analysis of the de-
gree of methylation versus age, which has also been
associated with T cell DNA hypomethylation (19,24),
did not indicate a statistically significant association
(P  0.211) in this group of patients, although the power
to detect an association was small.
The differences in methylation could reflect dif-
ferences in the methylation patterns of normal T cell
subsets. However, CD4 and CD8 T cells from a
healthy donor showed no differences, arguing against
this possibility (Figures 5A and B). Since the CD4
subset has been implicated in the pathogenesis of SLE
(6–10,25), the methylation pattern in the CD4 subset
was examined in a patient with active SLE (SLEDAI of
6) (Figure 5C). The ITGAL promoter was significantly
(P  0.027, by paired t-test) hypomethylated, indicating
that the changes can occur in this subset. The ITGAL
promoter was similarly hypomethylated in the CD8
Figure 6. Effect of T cell activation and DNA methylation inhibitors on ITGAL promoter methylation. The average
methylation from 1261 to 68 (identified by the solid squares) using A, unstimulated T cells, B, phytohemagglutinin
(PHA)–stimulated T cells, C, PHA-stimulated, 5-azacytidine (5-azaC)–treated T cells, and D, PHA-stimulated, procainamide
(Pca)–treated T cells is shown. In each case, the results represent the average methylation of 5 fragments from 3 individuals.
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subset from the same patient (Figure 5D), indicating
that both subsets are affected.
Since T cells from patients with active lupus are
frequently activated in vivo, it is possible that activation
contributed to the differences in methylation patterns.
To directly test this, T cells from 3 healthy donors were
stimulated for 3 days with PHA, and then methylation
patterns were compared. Figure 6A shows the methyl-
ation pattern across the same region in unstimulated T
cells, and 6B depicts the same region in the stimulated
cells. No differences were apparent, thus arguing against
a significant role for T cell activation.
Effect of DNA methylation inhibitors. Since the
DNA methylation inhibitors 5-azaC and procainamide
increase CD11a expression, and T cells treated with
these drugs cause a lupus-like disease (5–8), we exam-
ined the effect of these agents to determine whether they
demethylated the ITGAL promoter. Treating PHA-
stimulated T cells with 5-azaC caused significant hypo-
methylation of this region (mean 	 SEM fraction meth-
ylated 0.44 	 0.05 versus 0.26 	 0.04 for PHA-treated
versus 5-azaC–treated cells; P  0.048) (Figure 6C).
Similar results were observed in PHA-stimulated T cells
treated with procainamide (fraction methylated 0.30 	
0.02 versus 0.38 	 0.03 for procainamide-treated cells
versus control cells; P  0.01) (Figure 6D), although
procainamide appeared to be less potent than 5-azaC.
We determined the significance of the
procainamide-induced methylation changes by determin-
ing its effects on CD11a expression and autoreactivity.
Figure 7A compares CD11a expression on procainamide-
treated and untreated T cells. High- and low-expressing
subsets were seen within the untreated cell population,
which differed in fluorescence intensity by 3-fold (peak
fluorescence intensity 30 in the low-expressing subset and
100 in the high-expressing subset). It should be noted that
the data shown in Figure 7A are plotted as the channel in
arbitrary units, representing the log of the fluorescence
intensity. There was a shift of cells from the low-expressing
subset to the high-expressing subset in the treated cells,
resembling that seen in T cells from patients with active
lupus (Figure 1A). Procainamide similarly increased
CD11a mRNA 3.4-fold relative to -actin at the same
time point, as measured by quantitative real-time RT-
PCR (CD11a: -actin 0.54 in untreated cells versus 1.84
in procainamide-treated cells, determined relative to
standard curves that consisted of 5 serial dilutions of a
reference RNA preparation). Culturing the treated and
untreated cells with irradiated autologous PBMC dem-
onstrated that the treated cells were autoreactive (Fig-
ure 7B).
Effect of methylation on ITGAL promoter func-
tion. To determine the functional importance of meth-
ylation of the region variably methylated in the lupus
and drug-treated T cells, the region between the start of
the promoter (1950) and 382 was excised, methyl-
ated in vitro, ligated back into the luciferase reporter
construct, and transfected into Jurkat cells, using co-
transfection with -galactosidase as a control. Methyl-
ation decreased promoter expression by 40% (mean 	
SEM of 4 experiments luciferase:-galactosidase ratio
9.5 	 0.9 versus 5.7 	 0.5 for mock methylated versus
methylated cells; P  0.02, by paired t-test). The results
speak for the functional significance of the methylation
changes in this region.
ITGAL promoter methylation in RA. Peripheral
blood T cells from patients with RA can also have
hypomethylated DNA (11), although there is consider-
able interpatient variability, and relatively few of the
cells, if any, overexpress LFA-1 (9,26). To determine if
RA patients also have hypomethylated ITGAL promot-
ers, we analyzed methylation in T cells from 4 patients
Figure 7. Effect of procainamide (Pca) on T cell CD11a expression
and autoreactivity. Phytohemagglutinin (PHA)–stimulated T cells
were treated with procainamide as in Figure 6. A, CD11a expression
was compared on untreated (control) and Pca-treated cells. B, Un-
treated (control) and Pca-treated T cells were cultured with irradiated
autologous peripheral blood mononuclear cells (PBMCs) and prolif-
eration was measured 4 days later. Results are presented as the
mean 	 SEM of quadruplicate determinations. Positive controls
included stimulating untreated and treated T cells with 40,000 PBMCs
and 5 ng/ml PHA, resulting in proliferation of the untreated cells of
7,467 	 684 counts per minute (CPM), and of the treated cells of
8,820 	 1,149 CPM.
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with RA, of whom 3 had active disease and 1 had
inactive disease. The overall methylation was modestly
decreased (mean 	 SEM 0.34 	 0.07), but this was not
significantly different from that in controls, and there
was no evidence for LFA-1 overexpression (patient:
control MCF 0.91 	 0.32).
DISCUSSION
Although much of the interest in lupus has
focused on B cells since autoantibodies are a hallmark of
the disease, recent evidence suggests that T cells are
driving the autoantibody response. Nucleosome-reactive
T cells promote autoantibody synthesis in SLE (25), and
modification of T cells by genetic manipulation or DNA
hypomethylation can cause a lupus-like disease (6–8). T
cells from lupus patients demonstrate multiple biochem-
ical and functional abnormalities, including relative an-
ergy, altered signaling, and impaired protein synthesis
(27,28), suggesting profound biochemical abnormalities
in these cells. Included in these biochemical abnormal-
ities are decreased expression of DNA methyltrans-
ferase enzyme activity (11), decreased expression of
DNA methyltransferase 1 (Dnmt1) mRNA (17), and
globally hypomethylated DNA (11). Interestingly,
non–T peripheral blood mononuclear cells do not have
hypomethylated DNA (11), suggesting T cell specificity
for this abnormality. Since the DNA methyltransferases
mediate DNA methylation (22), it is likely that the
decreased enzyme activity contributes to the DNA hy-
pomethylation. The decreased Dnmt1 expression may be
due to decreased ERK pathway signaling, since inhibi-
tion of this signaling pathway leads to diminished Dnmt1
expression and DNA hypomethylation (17). Thus, sig-
naling abnormalities may contribute to DNA hypo-
methylation in SLE.
In this study, we have determined that DNA
hypomethylation in lupus affects sequences flanking the
ITGAL promoter. This gene was selected because it is
overexpressed following treatment with DNA methyl-
ation inhibitors (6–9), because LFA-1 overexpression
causes T cell autoreactivity in vitro and a lupus-like
disease in vivo (4,8), and because a similar LFA-1
overexpression occurs on an autoreactive T cell subset in
lupus (9,10). It is likely that DNA hypomethylation
affects other T cell genes in addition to ITGAL, and
recent studies using oligonucleotide arrays have demon-
strated that transcription of 100 known genes increases
following treatment with 5-azaC, including genes of
possible relevance to lupus, such as perforin and CD70
(Richardson B: unpublished observations). Whether the
same methylation-sensitive genes are affected in SLE
and whether they contribute to disease pathogenesis is at
present unknown, but these issues are addressable with
the use of approaches similar to those described in this
report.
The present study demonstrates that the 1,200-bp
region 5 to the transcription start site demethylates in T
cells from patients with active SLE, and that the degree
of hypomethylation is directly proportional to the sever-
ity of the flare as determined by the SLEDAI. The same
sequences also demethylate following treatment of nor-
mal T cells with 5-azaC or procainamide. Whereas the
200 bp immediately 5 to the start site, recognized by
transcription factors, is constitutively demethylated in
both lupus and control T cells, the demethylation of the
further 5 regions could be functionally significant.
Methylation suppresses transcription by targeting
methylcytosine-binding proteins to the relevant regions
of the DNA, and some methylcytosine-binding proteins,
such as MeCP2, suppress gene expression from a dis-
tance by promoting chromatin inactivation. MeCP2
binding to methylated cytosine bases attracts a
chromatin-inactivation complex containing histone
deacetylases as well as other proteins, which condense
chromatin into an inactive configuration (22). The patch
methylation studies indicate that methylation of these
sequences can, in fact, modify ITGAL promoter func-
tion, indicating that the demethylation occurring in SLE
can contribute to the LFA-1 overexpression.
Whether ITGAL promoter methylation patterns
are affected by mature T cell differentiation is unknown.
The data presented herein demonstrate that the decrease
in ITGAL promoter methylation occurs in the majority of
T cells from patients with active lupus, and analysis of the
CD4 population confirms that hypomethylation occurs in
these cells. This is relevant because autoreactive CD4 T
cells are responsible for the autoantibody response in this
disorder (7,9,29). In lupus, the most consistent finding in
this subset is in vivo activation (30). The present data
indicate that the patterns are not affected by PHA stimu-
lation, arguing against activation as a mechanism for the
hypomethylation, although it is possible that PHA stimu-
lation does not exactly mimic the in vivo conditions en-
countered by lupus T cells.
LFA-1 expression is also increased on memory T
cells relative to naive T cells. However, this increase is
associated with a parallel increase in CD2 expression
(31), and the increase in LFA-1 on lupus T cells is
independent of increased CD2 expression (9,10). This
indicates that different mechanisms contribute to LFA-1
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overexpression in lupus and in differentiation. Whether
the methylation pattern is different in a minor CD4
subset is uncertain, but the observation that class II–
restricted, LFA-1–overexpressing cells contain the auto-
reactive subset (9) supports the concept that the ITGAL
promoter hypomethylation observed may contribute to
the overexpression in autoreactive CD4 cells.
Other conditions, including RA and the pro-
cesses of aging, are associated with T cell DNA hypo-
methylation (11,24). The present study demonstrates
that the ITGAL promoter is not significantly hypo-
methylated in T cells from RA patients, and that LFA-1
is not overexpressed. This suggests that the methylation
changes may affect different sequences in RA T cells.
However, LFA-1 expression increases with age, as do
antinuclear antibodies (32,33). This raises the possibility
that progressive ITGAL demethylation may also contrib-
ute to some forms of autoimmunity in the elderly.
In summary, we have shown that regions flanking
the ITGAL promoter demethylate in T cells from pa-
tients with active SLE. We have also shown that demeth-
ylation of these sequences can contribute to increased
ITGAL promoter activity, and thus could lead to in-
creased LFA-1 expression, similar to that observed in T
cells treated with DNA methylation inhibitors, including
procainamide (5–9). Since LFA-1 overexpression is suf-
ficient to cause a lupus-like disease (8), these methyl-
ation changes could contribute to the development of
idiopathic and perhaps procainamide-induced SLE.
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Clinical Images: Epidural lipomatosis in a 14-year-old boy with systemic lupus erythematosus
The patient, a 14-year-old boy with systemic lupus erythematosus that had been treated with high-dose prednisone for 8 weeks,
presented with severe thoracolumbar back pain. Results of a neurologic examination were normal. Plain radiographs demonstrated
decreased bone mineralization but no fracture. T1-weighted sagittal (TR 500 msec/TE 22 msec) (A and B) and axial (TR 600
msec/TE 9 msec) (C) images of the spine revealed epidural lipomatosis, recognized as a marked increase in the amount of dorsal
epidural fat posterior to the cord (arrows). Note that the cerebrospinal fluid column is effaced in this region, with compression and
ventral displacement of the thecal sac and cord. Epidural lipomatosis may cause myelopathy, radiculopathy, back pain, and syrinx.
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